Tendyne Holdings is a clinical-stage medical device company developing technologies for transcatheter mitral valve replacement. The company provides a transcatheter mitral valve replacement prosthesis intended to treat both functional and degenerative mitral regurgitation. Its mitral valve is deployed and secured while preserving the sub-valvular apparatus and is initially implanted transapically. The implantation procedure allows the physician to re-position or retrieve the valve after full deployment. Tendyne intends to use recently raised funds to validate its Transcatheter Mitral Valve Implant and to support forthcoming clinical trials. Led by Founder and CEO Jeff Franco, the company is based in Roseville, MN.

Total raised

$25M

Funding rounds

1

Latest round

Series C

Latest activity

Apr 2014